Cytarabine, Idarubicin, and Lenalidomide

The combination of cytarabine, idarubicin, and lenalidomide is an investigational treatment regimen that has been studied primarily for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). This combination brings together conventional chemotherapy agents (cytarabine and idarubicin) with an immunomodulatory drug (lenalidomide).

Components of the Combination

Cytarabine is a standard chemotherapy drug used in AML treatment. It's a nucleoside analog that works by interfering with DNA synthesis, particularly affecting rapidly dividing cells like cancer cells. It's commonly administered as part of various AML treatment regimens, either at standard doses or high doses depending on the specific protocol.

Idarubicin is an anthracycline antineoplastic agent that is frequently used in AML treatment. It works by intercalating DNA and inhibiting topoisomerase II, which disrupts DNA replication and transcription in cancer cells.

Lenalidomide is an immunomodulatory drug that has been investigated as an addition to standard chemotherapy regimens to potentially improve outcomes in AML and MDS.

Clinical Evidence

A phase I study evaluated the combination of lenalidomide with cytarabine/idarubicin salvage chemotherapy in patients with relapsed/refractory AML and high-risk MDS. The study enrolled 33 patients (30 with AML, 3 with MDS) and determined that the maximum tolerated dose was:

• Lenalidomide 25 mg/day on days 1-21
• Cytarabine 1 g/m² on days 5-8
• Idarubicin 8 mg/m² on days 5-7

The study reported:

• Complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 18 patients (56%)
• One-year overall survival was 24%
• Two-year overall survival was 10%
• Among responders who underwent allogeneic hematopoietic cell transplantation, one-year overall survival was 40%

Dosing Regimens

Different dosing schedules have been investigated:

• In one protocol, patients received lenalidomide orally once daily on days 1-21, cytarabine intravenously continuously over 24 hours on days 5-11, and idarubicin according to a specific schedule.

• The maximum tolerated dose from the phase I study was lenalidomide 25 mg/day on days 1-21, cytarabine 1 g/m² on days 5-8, and idarubicin 8 mg/m² on days 5-7.

Side Effects and Toxicity

The combination therapy has significant toxicities. In the phase I study:

• Dose-limiting toxicity was observed in eight patients, including four hematologic dose-limiting toxicities
• Common non-hematologic serious adverse events included febrile neutropenia, rash, sepsis, and renal injury
• Only 45% of patients were able to receive the planned 21 days of lenalidomide

Current Status and Applications

This combination has shown clinical activity in relapsed/refractory AML and may be particularly valuable:

• For patients who have relapsed after hematopoietic cell transplantation
• As a bridge therapy to hematopoietic cell transplantation

The regimen continues to be investigated in clinical trials for AML and MDS, with ongoing research to determine optimal dosing, patient selection, and potential biomarkers of response.